Multimodal analysis based on high-field magnetic resonance and motor evoked potentials: A case report of multiple sclerosis

2016 ◽  
Vol 8 (1) ◽  
pp. 43-46
Author(s):  
Shunya Nakane ◽  
Kaori Furutani ◽  
Masafumi Harada ◽  
Ryo Urushihara ◽  
Naoko Matsui ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Magnetic Resonance ◽  
Evoked Potentials ◽  
High Field ◽  
Motor Evoked Potentials ◽  
Multimodal Analysis

Sensory (VEP, BAEP, SEP) and Motor-Evoked Potentials, Liquoral and Magnetic Resonance Findings in Multiple Sclerosis

1989 ◽  
Vol 29 (1) ◽  
pp. 41-47 ◽  
Author(s):  
P.M. Rossini ◽  
F. Zarola ◽  
R. Floris ◽  
G. Bernardi ◽  
A. Perretti ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Evoked Potentials ◽  
Motor Evoked Potentials

Motor evoked potentials in a mouse model of chronic multiple sclerosis

2006 ◽  
Vol 33 (2) ◽  
pp. 265-273 ◽  
Author(s):  
Stefano Amadio ◽  
Stefano Pluchino ◽  
Elena Brini ◽  
Paolo Morana ◽  
Roberta Guerriero ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mouse Model ◽  
Evoked Potentials ◽  
Motor Evoked Potentials

Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis

2010 ◽  
Vol 17 (2) ◽  
pp. 198-203 ◽  
Author(s):  
Sven G Meuth ◽  
Stefan Bittner ◽  
Carola Seiler ◽  
Kerstin Göbel ◽  
Heinz Wiendl
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Motor Evoked Potentials ◽  
Sum Score ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Sum Scores ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Background and Objective: The objective of this study was to examine the effects of natalizumab on functional parameters assessed by evoked potentials (visual [VEP], somatosensory [SEP] and motor evoked potentials [MEP]) in a cohort study in relapsing–remitting multiple sclerosis patients. Methods: EP data of 44 patients examined 12 months prior to natalizumab treatment, at the timepoint of treatment initiation and 1 year later were compared. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the Expanded Disability Status Scale. Results: Improvement of the VEP sum score was found in 33% of natalizumab-treated patients but only in 9% of the same patients prior to treatment ( p = 0.041). A comparable situation was found for SEP (improvement: 32% versus 5%; worsening: 11% versus 37%; p = 0.027). For MEP no significant differences were seen (improvement: 10% versus 18%; worsening: 5% versus 29%; p = 0.60). EP recordings (VEP = SEP > MEP) have the capacity to demonstrate treatment effects of natalizumab on a functional level. Conclusions: Natalizumab therapy increases the percentage of patients showing stable or even ameliorated electrophysiological parameters in the investigated functional systems.

Improvement in motor evoked potentials and clinical course post-steroid therapy in multiple sclerosis

1992 ◽  
Vol 108 (2) ◽  
pp. 184-188 ◽  
Author(s):  
J.Y. Salle ◽  
J. Hugon ◽  
F. Tabaraud ◽  
J.M. Boulesteix ◽  
J.M. Vallat ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Steroid Therapy ◽  
Clinical Course ◽  
Motor Evoked Potentials
Sign in / Sign up

Export Citation Format

Share Document